107. 若年性特発性関節炎 Disease details / Clinical trials / Drug dev / DR info

0.4ML prefilled syringes
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
0.7ML prefilled syringes
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
1ML prefilled syringes
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
331731-18-1
   AbbVie Deutschland GmbH & Co. KG
      2010   -   EUCTR2009-013091-40-SE   Czech Republic;France;Germany;Sweden
      2010   -   EUCTR2009-013091-40-CZ   Czech Republic;France;Germany;Sweden
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2009-013091-40-SK   Czech Republic;Denmark;France;Germany;Slovakia;Sweden
      2010   Phase 3   EUCTR2009-013091-40-FR   Czech Republic;Denmark;France;Germany;Slovakia;Sweden
      2010   Phase 3   EUCTR2009-013091-40-DK   Czech Republic;Denmark;France;Germany;Sweden
      2010   -   EUCTR2009-013091-40-DE   Czech Republic;France;Germany;Sweden
      -   -   EUCTR2009-013091-40-Outside-EU/EEA   -
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   F.I. Proctor Foundation, University of California San Francisco
      2019   Phase 4   EUCTR2019-000412-29-GB   Australia;United Kingdom;United States
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
   University Hospitals Bristol NHS Foundation Trust
      2011   Phase 2   EUCTR2010-021141-41-GB   United Kingdom
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
35MG
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
40 MG MSB11022
   Fresenius Kabi SwissBioSim GmbH
      2019   Phase 1   NCT04018599   United States
40 MG- soluzione iniettabile IN siringhe PRE-riempite- USO sottocutaneo- siringa preriempita (0,4ML)- 2 siringhe PRE-riempite + 2 tamponi imbevuti DI alcool
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
5MG
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
800 MG ibuprofen/26.6 MG famotidine
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01563185   United States
98-92-0
   UMC Utrecht
      2019   Phase 1;Phase 2   EUCTR2018-002245-11-NL   Netherlands
      -   Phase 1;Phase 2   EUCTR2016-003643-10-NL   Netherlands
Abatacept
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France
   Bristol-Myers Squibb
      2013   Phase 3   NCT01844518   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   NCT01835470   Japan
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   -   EUCTR2016-000940-32-Outside-EU/EEA   Japan
   Bristol-Myers Squibb K.K.
      2013   Phase 3   JPRN-jRCT2080222073   Japan
   Duke University
      2025   Phase 3   NCT06654882   -
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
   Yokohama City University Hospital Department of Pediatrics
      2016   -   JPRN-UMIN000024178   Japan
Abatacept injection
   Duke University
      2019   Phase 3   NCT03841357   United States
ABT-494
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 1   EUCTR2018-000715-25-IT   Germany;Hungary;Italy;Spain;Sweden;United States
   AbbVie Deutschland GmbH & Co. KG
      2023   Phase 1   EUCTR2018-000715-25-SE   Canada;Germany;Hungary;Italy;Spain;Sweden;United States
      2019   Phase 1   EUCTR2018-000715-25-HU   Germany;Hungary;Italy;Spain;United States
      2019   Phase 1;Phase 3   EUCTR2018-000715-25-ES   Germany;Hungary;Italy;Spain;United States
      2019   Phase 1   EUCTR2018-000715-25-DE   Germany;Hungary;Italy;Spain;Sweden;United States
Actemra
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-ES   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Ltd.
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
   Hoffmann-La Roche
      2013   Phase 3   NCT01727986   Brazil
      2012   Phase 3   NCT01673919   France
      2012   Phase 3   NCT01667471   Germany
      2012   Phase 3   NCT01575769   Poland;Russian Federation
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
   ROCHE
      2008   -   EUCTR2007-000872-18-IT   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
Actemra, MRA
   F. Hoffmann-La Roche Limited
      -   Phase 3   EUCTR2007-000872-18-NO   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
ACZ885
   NOVARTIS FARMA
      2009   -   EUCTR2008-008008-42-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
   NOVARTIS FARMA S.p.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-IT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
   NOVARTIS PHARMA AG
      2006   -   EUCTR2006-001834-42-IT   France;Italy;United Kingdom
   Novartis
      2006   Phase 1/Phase 2   NCT00426218   Italy
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003054-92-ES   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2009   -   EUCTR2008-008008-42-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005476-27-ES   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
   Novartis Pharma K.K.
      2015   Phase 3   JPRN-jRCT2080222813   -
   Novartis Pharma S.A.S
      2014   Phase 4   EUCTR2014-002872-95-FR   France
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-SE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-HU   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-DE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2013   -   EUCTR2012-003054-92-CZ   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-003054-92-AT   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2010   -   EUCTR2008-008008-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-008008-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2010   -   EUCTR2008-005479-82-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005476-27-GR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005476-27-GB   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-SE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-NL   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-HU   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-GB   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-005479-82-SE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-HU   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-GB   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005479-82-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-DE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005479-82-BE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-AT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-SE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-HU   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005476-27-FR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-DK   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-DE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-BE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2012-003054-92-BE   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2008-008008-42-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      -   -   EUCTR2008-005479-82-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Switzerland;Turkey;United States
      -   Phase 3   EUCTR2008-005479-82-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      -   -   EUCTR2008-005476-27-Outside-EU/EEA   Argentina;Brazil;Israel;Peru;Switzerland;Turkey;United States
      -   Phase 3   EUCTR2008-005476-27-NO   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Novartis PharmaServices AG
      -   -   EUCTR2008-008008-42-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
   Novartis Pharmaceuticals
      2014   Phase 3   NCT02296424   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2013   Phase 3   NCT01676948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
ACZ885 drug substance
   Novartis Pharma Services AG
      2007   Phase 2   EUCTR2006-001834-42-GB   France;Italy;United Kingdom
      2007   -   EUCTR2006-001834-42-FR   France;Italy;United Kingdom
ACZ885G
   NOVARTIS FARMA
      2009   -   EUCTR2008-005476-27-IT   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
AD26.COV2.S
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Adalimumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   AbbVie
      2008   -   NCT00783510   Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00775437   Czech Republic;Denmark;France;Germany;Puerto Rico;Slovakia;Sweden;United States
   AbbVie Deutschland GmbH & Co. KG
      2010   -   EUCTR2009-013091-40-SE   Czech Republic;France;Germany;Sweden
      2010   -   EUCTR2009-013091-40-CZ   Czech Republic;France;Germany;Sweden
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2009-013091-40-SK   Czech Republic;Denmark;France;Germany;Slovakia;Sweden
      2010   Phase 3   EUCTR2009-013091-40-FR   Czech Republic;Denmark;France;Germany;Slovakia;Sweden
      2010   Phase 3   EUCTR2009-013091-40-DK   Czech Republic;Denmark;France;Germany;Sweden
      2010   -   EUCTR2009-013091-40-DE   Czech Republic;France;Germany;Sweden
      -   -   EUCTR2009-013091-40-Outside-EU/EEA   -
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   NCT04088409   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   F.I. Proctor Foundation, University of California San Francisco
      2019   Phase 4   EUCTR2019-000412-29-GB   Australia;United Kingdom;United States
   Nisha Acharya
      2020   Phase 4   NCT03816397   Australia;United Kingdom;United States
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
   University Hospitals Bristol NHS Foundation Trust
      2011   Phase 2   EUCTR2010-021141-41-GB   United Kingdom
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
Adalimumab biosimilare
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
AIN457
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2018-002521-30-IT   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2017   Phase 3   EUCTR2016-003761-26-ES   Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 3   EUCTR2018-002521-30-ES   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2018-002521-30-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
      2019   Phase 3   EUCTR2018-002521-30-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2017   Phase 3   EUCTR2016-003761-26-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-GB   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2018-002521-30-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
   Novartis Pharmaceuticals
      2019   Phase 3   NCT03769168   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
AIN457F
   NOVARTIS PHARMA AG
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
Alemtuzumab
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
Alfacalcidol 2 micrograms/ML
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
Allogeneic hope biosciences adipose-derived mesenchymal stem cells
   Hope Biosciences
      2025   Phase 2   NCT06623240   United States
Ambirix
   Public Health Service Amsterdam
      2009   -   EUCTR2008-003280-40-NL   Netherlands
AMG 407
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
AMG-407
   Amgen Inc.
      2022   Phase 3   EUCTR2019-002788-88-RO   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Türkiye;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-PT   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2022   Phase 3   EUCTR2019-002788-88-LT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-GR   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
AMG407
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain
   Amgen Inc.
      2022   Phase 3   EUCTR2019-002788-88-RO   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Türkiye;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-PT   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2022   Phase 3   EUCTR2019-002788-88-LT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-GR   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
Anakinra
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-004008-36-IT   Italy
   Institut National de la Santé Et de la Recherche Médicale, France
      2006   Phase 2/Phase 3   NCT00339157   France
   Swedish Orphan Biovitrum
      2019   -   NCT03932344   Italy
   Takeshi KUROSAWA
      2023   Phase 3   JPRN-jRCT2031220222   -
Anakinra / kineret
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
ANTI-TNF
   University of Sao Paulo
      2008   Phase 4   NCT02196480   Brazil
ANTI-tumor necrosis factor alpha monoclonal antibody
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2/Phase 3   NCT01385826   France
Antivirale AD USO diretto
   Swedish Orphan Biovitrum AG
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
APD421
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 66 Hudson Boulevard East, New York, New York 10001
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
Apremilast 10 MG
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain
   Amgen Inc.
      2022   Phase 3   EUCTR2019-002788-88-RO   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Türkiye;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-PT   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2022   Phase 3   EUCTR2019-002788-88-LT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-GR   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
Apremilast 20 MG
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc.
      2022   Phase 3   EUCTR2019-002788-88-RO   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Türkiye;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-PT   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2022   Phase 3   EUCTR2019-002788-88-LT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-GR   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
Apremilast 30 MG
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc.
      2022   Phase 3   EUCTR2019-002788-88-RO   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Türkiye;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-PT   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2022   Phase 3   EUCTR2019-002788-88-LT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-GR   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
Baricitinib
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-IT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
   Eli Lilly Japan K.K.
      2019   Phase 3   JPRN-jRCT2080224972   Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;India;Israel;Italy;Japan;Mexico;Poland;Spain;Turkey;United Kingdom
   Eli Lilly and Company
      2020   Phase 3   NCT04088396   Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   NCT04088409   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   NCT03773965   Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-PL   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-GB   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-FR   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-DK   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-BE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2018   Phase 3   NCT03773978   Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-DE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-CZ   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-AT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004471-31-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Türkiye;United Kingdom
   Lilly S.A.
      2019   Phase 3   EUCTR2017-004518-24-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
Bimekizumab
   UCB Biopharma SRL
      2025   Phase 3   NCT06668181   Canada;France;Germany;Poland;Spain;United Kingdom
Biologic dmards
   Kasr El Aini Hospital
      2022   Phase 4   NCT05540743   Egypt
Biological dmards
   Hoffmann-La Roche
      2000   -   NCT02784808   -
Biological drug
   IRCCS Burlo Garofolo
      2025   -   NCT06895278   Italy
Biosimilar adalimumab
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
Biosimilar etanercept
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2023   -   NCT05534347   France
   University Hospital, Montpellier
      2014   -   NCT02067962   -
BMS-188667
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   -   EUCTR2016-000940-32-Outside-EU/EEA   Japan
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States
BNT162b2, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
BOF-, mazelen-, rubellavaccin, poeder voor injectievloeistof
   University Medical Center Utrecht
      2008   -   EUCTR2007-001861-14-NL   Netherlands
Canakinumab
   NOVARTIS FARMA
      2009   -   EUCTR2008-008008-42-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-IT   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
   NOVARTIS FARMA S.p.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-IT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003054-92-ES   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2009   -   EUCTR2008-008008-42-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005476-27-ES   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
   Novartis Pharma K.K.
      2015   Phase 3   JPRN-jRCT2080222813   -
   Novartis Pharma S.A.S
      2014   Phase 4   EUCTR2014-002872-95-FR   France
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-SE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-HU   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-DE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2013   -   EUCTR2012-003054-92-CZ   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-003054-92-AT   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2010   -   EUCTR2008-008008-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-008008-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2010   -   EUCTR2008-005479-82-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005476-27-GR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005476-27-GB   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-SE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-NL   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-HU   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-GB   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-005479-82-SE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-HU   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-GB   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005479-82-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-DE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005479-82-BE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-AT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-SE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-HU   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005476-27-FR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-DK   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-DE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-BE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2012-003054-92-BE   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2008-008008-42-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      -   -   EUCTR2008-005479-82-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Switzerland;Turkey;United States
      -   Phase 3   EUCTR2008-005479-82-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      -   -   EUCTR2008-005476-27-Outside-EU/EEA   Argentina;Brazil;Israel;Peru;Switzerland;Turkey;United States
      -   Phase 3   EUCTR2008-005476-27-NO   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Novartis PharmaServices AG
      -   -   EUCTR2008-008008-42-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
   Novartis Pharmaceuticals
      2015   Phase 3   NCT02396212   Japan
      2014   Phase 3   NCT02334748   France
      2014   Phase 3   NCT02296424   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United States
      2013   Phase 3   NCT01676948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   Phase 3   NCT00891046   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   Phase 3   NCT00889863   Argentina;Belgium;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United States
      2009   Phase 3   NCT00886769   Argentina;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Celebrex
   Pfizer Inc
      -   -   EUCTR2014-003737-26-Outside-EU/EEA   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States
Celecoxib
   Pfizer Inc
      -   -   EUCTR2014-003737-26-Outside-EU/EEA   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 4   NCT00807846   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States
      2009   -   NCT00688545   United States
Certolizumab pegol
   UCB BIOSCIENCES GmbH
      2012   Phase 3   NCT01550003   Argentina;Brazil;Canada;Chile;Mexico;Netherlands;Russian Federation;United States
      -   Phase 3   EUCTR2009-018027-33-Outside-EU/EEA   Argentina;Brazil;Canada;Chile;Mexico;Russian Federation;United States
Cervarix suspensie voor injectie
   University Medical Center Utrecht
      2009   -   EUCTR2008-008169-36-NL   Netherlands
Cimzia
   UCB BIOSCIENCES GmbH
      -   Phase 3   EUCTR2009-018027-33-Outside-EU/EEA   Argentina;Brazil;Canada;Chile;Mexico;Russian Federation;United States
CNTO148
   Janssen Biologics B.V.
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States
Coenzyme Q10
   Nourhan Elsherif
      2023   Phase 2/Phase 3   NCT05871086   Egypt
Collection OF samples
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   -   NCT04902807   -
Combination OF dmards
   Helsinki University Central Hospital
      2003   Phase 3   NCT01015547   Finland
Complete, polymeric formula, fiber, lactose and gluten free
   Meyer Children's Hospital IRCCS
      2024   -   NCT06874608   Italy
Corticosteroids
   Hoffmann-La Roche
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
Cosentyx
   NOVARTIS PHARMA AG
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2017   Phase 3   EUCTR2016-003761-26-ES   Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 3   EUCTR2018-002521-30-ES   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2018-002521-30-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
      2019   Phase 3   EUCTR2018-002521-30-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2017   Phase 3   EUCTR2016-003761-26-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-GB   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2018-002521-30-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
Cosentyx - 150 MG - soluzione iniettabile IN siringa preriempita -USO sottocutaneo - siringa (vetro) 1 ML (150MG/ML)- 2 siringhe preriempite
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2018-002521-30-IT   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
CP-690,550
   Pfizer
      2016   Phase 3   NCT02592434   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2013   Phase 1   NCT01513902   Germany;Hungary;Poland;Slovakia;United States
CP-690,550-10
   PFIZER INC
      2020   Phase 3   EUCTR2017-002018-29-IT   Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   PFIZER INC.
      2013   Phase 2   EUCTR2011-004915-22-IT   Argentina;Belgium;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;United Kingdom
      2012   -   EUCTR2011-004914-40-IT   Argentina;Hungary;Italy;Mexico;Poland;Russian Federation
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2011-004914-40-SK   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia
      2012   -   EUCTR2011-004914-40-PL   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia
      2012   Phase 1   EUCTR2011-004914-40-HU   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2022   Phase 2;Phase 3   EUCTR2011-004915-22-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2015-001438-46-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-HU   Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 66 Hudson Boulevard East, New York, New York 10001
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
CP-690-550-10
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 66 Hudson Boulevard East, New York, New York 10001
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
CSS
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China
Cyclosporin
   Children's Hospital, Zhejiang University School of Medicine
      2023   Phase 0   ChiCTR2300070171   China
Cyclosporine
   Children's Hospital, Zhejiang University School of Medicine
      2023   Phase 0   ChiCTR2300070171   China
Cyclosporine A
   St. Franziskus Hospital
      1991   -   NCT00404482   Germany
Daclizumab
   National Eye Institute (NEI)
      2005   Phase 2   NCT00130637   United States
Dexmedetomidine
   University of Oulu
      2017   Phase 4   NCT03069638   Finland
Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-YL methyl]-ammonium chloride
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic
Double-blind adalimumab
   Abbott
      2002   Phase 3   NCT00048542   Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States
Emapalumab
   Novimmune SA
      2018   Phase 2   EUCTR2016-004223-23-NL   Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004223-23-ES   France;Germany;Italy;Netherlands;Spain;United Kingdom
      -   Phase 2   EUCTR2016-004223-23-FR   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
   Ochiai Kazuya
      2023   Phase 2-3   JPRN-jRCT2031220187   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Swedish Orphan Biovitrum
      2018   Phase 2   NCT03311854   France;Italy;Netherlands;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AG
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AG (Sobi AG)
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-NL   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-DE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-CZ   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-BE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-PL   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-FR   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-ES   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-001577-24-SE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Enbrel
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
      -   -   EUCTR2012-001171-37-Outside-EU/EEA   Canada;United States
      -   -   EUCTR2012-001145-40-Outside-EU/EEA   Canada;United States
   Asklepios Klinik Sankt Augustin
      2011   -   EUCTR2010-020423-51-DE   Germany
   Asklepios-Klinik Sankt Augustin
      2007   -   EUCTR2007-000255-34-DE   Germany
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy
   PFIZER INC.
      2012   -   EUCTR2010-023802-10-IT   Australia;Belgium;Colombia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Russian Federation;Slovakia;Slovenia;Spain
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   Phase 3   EUCTR2010-023802-10-NO   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-SK   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-SI   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-LV   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-LT   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-HU   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-FR   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-DE   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-CZ   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-BE   Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      -   Phase 3   EUCTR2010-023802-10-PL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      -   -   EUCTR2010-023802-10-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
   Wyeth Kabushiki Kaisha (Wyeth K.K.)
      -   -   EUCTR2014-004103-73-Outside-EU/EEA   Japan
   Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
      2010   -   EUCTR2009-012520-84-CZ   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-SI   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-LV   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-LT   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-DE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   Phase 3   EUCTR2009-012520-84-BE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden
      -   -   EUCTR2009-012520-84-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   Phase 3   EUCTR2009-012520-84-SK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
      2010   -   EUCTR2009-012520-84-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2010   -   EUCTR2009-012520-84-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2010   Phase 3   EUCTR2009-012520-84-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2009   Phase 3   EUCTR2009-012520-84-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden
Enbrel 25 MG/ML polvo Y disolvente para solucióN inyectable para USO pediátrico
   PFIZER, S.L.U.
      2011   Phase 3   EUCTR2010-023802-10-ES   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
      2012   Phase 3   EUCTR2010-023802-10-NL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
Enbrel 50 MG solucióN inyectable EN jeringas precargadas
   PFIZER, S.L.U.
      2011   Phase 3   EUCTR2010-023802-10-ES   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
      2012   Phase 3   EUCTR2010-023802-10-NL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
Enbrel*BB SC 4FL 25MG 1ML+4SIR
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2010   -   EUCTR2009-012520-84-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
Entecavir
   Seoul National University Hospital
      2012   Phase 3   NCT01694264   Korea, Republic of
Esomeprazole
   AstraZeneca
      2011   Phase 1   NCT01358383   United States
Etanercept
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
      -   -   EUCTR2012-001171-37-Outside-EU/EEA   Canada;United States
      -   -   EUCTR2012-001145-40-Outside-EU/EEA   Canada;United States
   Asklepios-Klinik Sankt Augustin
      2007   -   EUCTR2007-000255-34-DE   Germany
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France
   Erasmus Medical Center
      2011   Phase 4   NCT01287715   Netherlands
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy
   PFIZER INC.
      2012   -   EUCTR2010-023802-10-IT   Australia;Belgium;Colombia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Russian Federation;Slovakia;Slovenia;Spain
   PFIZER, S.L.U.
      2011   Phase 3   EUCTR2010-023802-10-ES   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
   Pfizer
      2011   Phase 3   NCT01421069   Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2009   -   NCT01145352   Japan
      2009   Phase 3   NCT00962741   Argentina;Australia;Belgium;Brazil;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;Sweden;Taiwan
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
      2012   Phase 3   EUCTR2010-023802-10-NL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   Phase 3   EUCTR2010-023802-10-NO   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-SK   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-SI   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-LV   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-LT   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-HU   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-FR   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-DE   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-CZ   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      2011   Phase 3   EUCTR2010-023802-10-BE   Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      -   Phase 3   EUCTR2010-023802-10-PL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain
      -   -   EUCTR2010-023802-10-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
   Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
      2010   -   EUCTR2009-012520-84-CZ   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-SI   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-LV   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-LT   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-DE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden
      2009   Phase 3   EUCTR2009-012520-84-BE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden
      -   -   EUCTR2009-012520-84-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   Phase 3   EUCTR2009-012520-84-SK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
      2010   -   EUCTR2009-012520-84-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2010   -   EUCTR2009-012520-84-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2010   -   EUCTR2009-012520-84-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2010   Phase 3   EUCTR2009-012520-84-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2009   -   EUCTR2009-012520-84-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden
      2009   Phase 3   EUCTR2009-012520-84-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   -   NCT00195377   Spain
Etanercept biosimilar
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
Etanercept biosimilare
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
Etanercept optimal dosing
   Duke University
      2025   Phase 1   NCT04585711   United States
EU/1/03/256/001
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
EU/1/07/389/001
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
EU/1/99/126/001
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
EX vivo cultured human mesenchymal stem cells
   University Medical Center Utrecht
      2014   -   EUCTR2012-002067-10-NL   Netherlands
Fibrinogen
   Assiut University
      2023   -   NCT06024486   -
Filgotinib
   Alfasigma S.p.A.
      2024   Phase 1   NCT06222034   France;Germany;Poland;Spain;United Kingdom
Fludarabine
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
Folic/folinic acid
   University of British Columbia
      2019   -   NCT04169828   Canada
Fully human ANTI-interferon gamma monoclonal antibody
   Novimmune SA
      -   Phase 2   EUCTR2016-004223-23-FR   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
Genakumab
   Changchun GeneScience Pharmaceutical Co., Ltd.
      2023   -   NCT05925452   China
   GeneScience Pharmaceuticals Co., Ltd.
      2019   Phase 1   NCT04337437   China
Genicular nerve block
   Sohag University
      2020   Phase 4   NCT04687930   Egypt
Genotropin
   Ludwig-Maximilians - University of Munich
      1996   Phase 3   NCT00420251   Germany
   Pfizer Inc
      -   -   EUCTR2014-004105-32-Outside-EU/EEA   France
   Pharmacia & Upjohn S.A.
      -   -   EUCTR2014-004104-30-Outside-EU/EEA   France
Givinostat
   ITALFARMACO
      2010   -   EUCTR2010-019094-15-IT   Czech Republic;Italy;Slovenia;Spain
   Italfarmaco
      2011   -   NCT01557452   Czech Republic
      2010   Phase 2   NCT01261624   Belgium;Czech Republic;Italy;Romania;Serbia;Slovenia;Spain
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic
      2010   -   EUCTR2010-019094-15-SI   Czech Republic;Italy;Slovenia;Spain
      2010   -   EUCTR2010-019094-15-ES   Czech Republic;Italy;Slovenia;Spain
      2010   -   EUCTR2010-019094-15-CZ   Czech Republic;Italy;Slovenia;Spain
      2010   Phase 2   EUCTR2010-019094-15-BE   Belgium;Czech Republic;Italy;Slovenia;Spain
Golimumab
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02277444   Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States
      2010   Phase 3   NCT01230827   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States
   Medical University of Graz
      2010   -   NCT04200833   -
Golimumab liquid IN prefilled syringe
   Janssen Biologics B.V.
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States
Growth hormone
   Royal Hospital For Sick Children, Yorkhill Division
      2004   -   EUCTR2004-004153-25-GB   United Kingdom
Heparin
   Shanghai Children's Medical Center
      2015   -   ChiCTR-OOC-15006228   China
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Human ANTI-TNF-alpha monoclonal antibody
   Janssen Biologics B.V.
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States
Humira
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   AbbVie Deutschland GmbH & Co. KG
      2010   -   EUCTR2009-013091-40-SE   Czech Republic;France;Germany;Sweden
      2010   -   EUCTR2009-013091-40-CZ   Czech Republic;France;Germany;Sweden
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2009-013091-40-SK   Czech Republic;Denmark;France;Germany;Slovakia;Sweden
      2010   Phase 3   EUCTR2009-013091-40-FR   Czech Republic;Denmark;France;Germany;Slovakia;Sweden
      2010   Phase 3   EUCTR2009-013091-40-DK   Czech Republic;Denmark;France;Germany;Sweden
      2010   -   EUCTR2009-013091-40-DE   Czech Republic;France;Germany;Sweden
      -   -   EUCTR2009-013091-40-Outside-EU/EEA   -
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   F.I. Proctor Foundation, University of California San Francisco
      2019   Phase 4   EUCTR2019-000412-29-GB   Australia;United Kingdom;United States
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
Hydroxychloroquine
   Leiden University Medical Centre
      2016   Phase 4   EUCTR2014-003260-20-NL   Netherlands
Hydroxyurea
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
IL-1 trap
   Regeneron Pharmaceuticals
      2005   Phase 1   NCT01803321   United States
IL-6 receptor inhibitor, recombinant humanized monoclonal antibody
   F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-PL   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-HU   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-GB   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-DE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-BE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 1   EUCTR2015-000435-33-FR   Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-ES   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
Ilaris
   Asklepios Klink Sankt Augustin
      2020   Phase 4   EUCTR2018-004284-30-DE   Germany
   NOVARTIS FARMA
      2009   -   EUCTR2008-005479-82-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-IT   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003054-92-ES   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States
   Novartis Pharma S.A.S
      2014   Phase 4   EUCTR2014-002872-95-FR   France
   Novartis Pharma Services AG
      2013   -   EUCTR2012-003054-92-CZ   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-003054-92-AT   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2010   -   EUCTR2008-008008-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-NL   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-HU   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2012-003054-92-BE   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      -   -   EUCTR2008-005479-82-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Switzerland;Turkey;United States
      -   -   EUCTR2008-005476-27-Outside-EU/EEA   Argentina;Brazil;Israel;Peru;Switzerland;Turkey;United States
   Novartis PharmaServices AG
      -   -   EUCTR2008-008008-42-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States
   Novartis Pharmaceuticals
      2025   -   NCT06838143   -
IN double-blind phase: treatment with tofacitinib
   Pfizer
      2018   Phase 3   NCT03000439   Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
IN OPEN-label phase: treatment with tofacitinib
   Pfizer
      2018   Phase 3   NCT03000439   Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States
Infliximab plus methotrexate
   Helsinki University Central Hospital
      2003   Phase 3   NCT01015547   Finland
Influenza vaccine, immune function
   University of Pecs
      2018   Early Phase 1   NCT03833271   Hungary
Intra-articular steroid injection
   Sohag University
      2020   Phase 4   NCT04687930   Egypt
ITF2357
   ITALFARMACO
      2010   -   EUCTR2010-019094-15-IT   Czech Republic;Italy;Slovenia;Spain
      2006   -   EUCTR2006-000089-35-IT   Italy
   Italfarmaco
      2006   Phase 2   NCT00570661   Former Serbia and Montenegro;Serbia
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic
      2010   -   EUCTR2010-019094-15-SI   Czech Republic;Italy;Slovenia;Spain
      2010   -   EUCTR2010-019094-15-ES   Czech Republic;Italy;Slovenia;Spain
      2010   -   EUCTR2010-019094-15-CZ   Czech Republic;Italy;Slovenia;Spain
      2010   Phase 2   EUCTR2010-019094-15-BE   Belgium;Czech Republic;Italy;Slovenia;Spain
Ixekizumab
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
Joint puncture
   Assistance Publique - Hôpitaux de Paris
      2023   -   NCT05534347   France
Kineret*SC 7SIR 100MG 0,67ML
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-004008-36-IT   Italy
Kineret® or anakinra
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands
L01ba01
   ISTITUTO GIANNINA GASLINI-PRINTO
      2005   Phase 3   EUCTR2005-001086-34-DK   Denmark;Italy;Spain
   Istituto Giannina Gaslini-PRINTO
      2005   -   EUCTR2005-001086-34-ES   Denmark;Italy;Spain
L04ab04
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
   Eli Lilly and Company
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
Lederspan
   Oslo University Hospital
      2020   Phase 4   EUCTR2019-000889-38-NO   Norway
Leflunomide
   Mashhad University of Medical Sciences
      2013   Phase 4   NCT02024334   Iran, Islamic Republic of
Lidocaine
   Sohag University
      2021   Phase 3   NCT04775225   Egypt
LY2439821
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
LY3009104
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-IT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
   Eli Lilly Japan K.K.
      2019   Phase 3   JPRN-jRCT2080224972   Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;India;Israel;Italy;Japan;Mexico;Poland;Spain;Turkey;United Kingdom
   Eli Lilly and Company
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-PL   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-GB   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-FR   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-DK   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-BE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-DE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-CZ   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-AT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004471-31-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Türkiye;United Kingdom
   Lilly S.A.
      2019   Phase 3   EUCTR2017-004518-24-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
M-M-rvaxpro
   University Medical Center Utrecht
      2008   -   EUCTR2007-001861-14-NL   Netherlands
Measles, mumps, rubella vaccination
   N.M. Wulffraat
      2008   Phase 4   NCT00731965   Netherlands
Melphalan
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
Mesenchymal stem cells
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2025   Phase 1/Phase 2   NCT06888973   Pakistan
Mesenchymal stromal cells
   University Medical Center Utrecht
      2014   -   EUCTR2012-002067-10-NL   Netherlands
Methotrexate
   AbbVie
      2008   -   NCT00783510   Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States
   Hoffmann-La Roche
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
   IRCCS Burlo Garofolo
      2025   -   NCT06895278   Italy
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-001086-34-IT   Denmark;Italy;Spain
   ISTITUTO GIANNINA GASLINI-PRINTO
      2005   Phase 3   EUCTR2005-001086-34-DK   Denmark;Italy;Spain
   Institute of Child Health
      2006   -   NCT00415935   United Kingdom
   Istituto Giannina Gaslini-PRINTO
      2005   -   EUCTR2005-001086-34-ES   Denmark;Italy;Spain
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02277444   Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States
      2010   Phase 3   NCT01230827   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States
   Leiden University
      -   Phase 4   EUCTR2018-001571-21-NL   Netherlands
   Leiden University Medical Centre
      2016   Phase 4   EUCTR2014-003260-20-NL   Netherlands
   Oslo University Hospital
      2024   Phase 4   NCT06653634   Norway
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
   University of British Columbia
      2019   -   NCT04169828   Canada
Methotrexate - etanercept - prednisolone ARM
   Seattle Children's Hospital
      2007   Phase 4   NCT00443430   United States
Methotrexate alone
   Helsinki University Central Hospital
      2003   Phase 3   NCT01015547   Finland
Methotrexate disodium
   University of Munster
      2008   Phase 4   EUCTR2006-006812-31-DE   Germany;Netherlands
   university medical centre utrecht
      2007   Phase 4   EUCTR2006-006812-31-NL   Germany;Netherlands
Methotrexate prefilled PEN
   medac GmbH
      2014   Early Phase 1   NCT02052167   United States
Methotrexate*25CPR 2,5MG
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2008-006741-70-IT   Italy
Metoject
   University of Munster
      2008   Phase 4   EUCTR2006-006812-31-DE   Germany;Netherlands
   university medical centre utrecht
      2007   Phase 4   EUCTR2006-006812-31-NL   Germany;Netherlands
Metotrexato
   Istituto Giannina Gaslini-PRINTO
      2005   -   EUCTR2005-001086-34-ES   Denmark;Italy;Spain
MMF
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Moderna MRNA-1273, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Monohydrate
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic
      2010   -   EUCTR2010-019094-15-SI   Czech Republic;Italy;Slovenia;Spain
      2010   -   EUCTR2010-019094-15-ES   Czech Republic;Italy;Slovenia;Spain
      2010   -   EUCTR2010-019094-15-CZ   Czech Republic;Italy;Slovenia;Spain
      2010   Phase 2   EUCTR2010-019094-15-BE   Belgium;Czech Republic;Italy;Slovenia;Spain
Monovalent [B.1.351] COV2 pres DTM-AS03
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MPA
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MRA
   Chugai Pharmaceutical
      2005   Phase 3   NCT00144625   -
      2004   Phase 3   NCT00144664   -
      2004   Phase 3   NCT00144612   -
      2004   Phase 3   NCT00144599   -
   Chugai Pharmaceutical Co., Ltd.
      2005   Phase 3   JPRN-jRCT2080220017   -
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Ltd.
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
MRA, actemra
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SE   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-NL   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
MTX
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Naproxen
   AstraZeneca
      2011   Phase 1   NCT01358383   United States
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 4   NCT00807846   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States
Naproxen sodium
   Pfizer Inc
      -   -   EUCTR2014-003737-26-Outside-EU/EEA   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States
NI-0501
   Novimmune SA
      2018   Phase 2   EUCTR2016-004223-23-NL   Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004223-23-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004223-23-ES   France;Germany;Italy;Netherlands;Spain;United Kingdom
      -   Phase 2   EUCTR2016-004223-23-FR   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AG
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AG (Sobi AG)
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-NL   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-DE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-CZ   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-BE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-PL   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-FR   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-ES   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-001577-24-SE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Nicotinamide
   UMC Utrecht
      2019   Phase 1;Phase 2   EUCTR2018-002245-11-NL   Netherlands
      -   Phase 1;Phase 2   EUCTR2016-003643-10-NL   Netherlands
NON-biologic dmards
   Hoffmann-La Roche
      2000   -   NCT02784808   -
Norditropin simplexx 5MG/1.5ML
   Royal Hospital For Sick Children, Yorkhill Division
      2004   -   EUCTR2004-004153-25-GB   United Kingdom
Nsaids
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
Nsnsaids
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   -   NCT00688545   United States
OLE BSA adalimumab +/- MTX
   Abbott
      2002   Phase 3   NCT00048542   Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States
OLE FD adalimumab +/- MTX
   Abbott
      2002   Phase 3   NCT00048542   Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States
Olumiant
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-IT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
   Eli Lilly and Company
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004518-24-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-PL   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-GB   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-FR   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-DK   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004495-60-BE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-DE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-CZ   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004495-60-AT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004471-31-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Türkiye;United Kingdom
   Lilly S.A.
      2019   Phase 3   EUCTR2017-004518-24-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004471-31-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
Oluminant
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
Ondansetron
   University of British Columbia
      2019   -   NCT04169828   Canada
ONE alpha drops
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
ONE-alpha drops
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
Orencia
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
Originator adalimumab
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy
Otezla
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc.
      2022   Phase 3   EUCTR2019-002788-88-RO   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Türkiye;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-PT   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2022   Phase 3   EUCTR2019-002788-88-LT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2022   Phase 3   EUCTR2019-002788-88-GR   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal
      2021   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Germany;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Greece;Italy;Lithuania;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Turkey;United Kingdom
Otezla - 10 MG + 20 MG + 30 MG compressa rivestita CON film USO orale - blister (PVC/ALU) IN UN astuccio - 4 compresse DA 10 MG + 4 compresse DA 20 MG +19 compresse DA 30 MG
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain
Pneumo23
   Institut National de la Santé Et de la Recherche Médicale, France
      2006   Phase 2/Phase 3   NCT00339157   France
PRE-filled syringe
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   F. Hoffmann-La Roche Ltd
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   F.I. Proctor Foundation, University of California San Francisco
      2019   Phase 4   EUCTR2019-000412-29-GB   Australia;United Kingdom;United States
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy
   Novartis Farmacéutica S.A.
      2017   Phase 3   EUCTR2016-003761-26-ES   Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 3   EUCTR2018-002521-30-ES   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2018-002521-30-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
      2019   Phase 3   EUCTR2018-002521-30-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2017   Phase 3   EUCTR2016-003761-26-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-GB   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2018-002521-30-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands
   Wyeth Kabushiki Kaisha (Wyeth K.K.)
      -   -   EUCTR2014-004103-73-Outside-EU/EEA   Japan
Profilassi PER herpes zoster
   Swedish Orphan Biovitrum AG
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Quadrivalent HPV vaccine
   The University of New South Wales
      2007   Phase 3   NCT02263703   Australia
Recombinant antihumanized ANTI-human monoclonal antibody directed against THE IL-6R
   F. Hoffmann-La Roche Ltd
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
Recombinant human monoclonal antibody TO human IL-1beta OF THE IGG1/K class
   Novartis Farmacéutica S.A.
      2009   -   EUCTR2008-008008-42-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005476-27-ES   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Novartis Pharma Services AG
      2010   -   EUCTR2008-008008-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005479-82-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005476-27-GR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2010   -   EUCTR2008-005476-27-GB   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-SE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-GB   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-008008-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-008008-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2009   -   EUCTR2008-005479-82-SE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-HU   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-GB   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005479-82-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-DE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005479-82-BE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005479-82-AT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-SE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-HU   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2008-005476-27-FR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-DK   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-DE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-005476-27-BE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2008-008008-42-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2008-005479-82-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2008-005476-27-NO   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
Recombinant humanized ANTI-human monoclonal antibody directed against THE IL-6R
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
REGN88
   Sanofi
      2018   Phase 2   NCT02991469   Argentina;Bulgaria;Canada;Chile;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   sanofi-aventis recherche & développement
      2021   Phase 2   EUCTR2015-004000-35-IE   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2021   Phase 2   EUCTR2015-004000-35-BG   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2015-004000-35-PL   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-NL   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-DE   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-003999-79-DE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-IT   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-FI   Argentina;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-ES   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-EE   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-PL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-NL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-IT   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-FI   Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-ES   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-CZ   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-004000-35-CZ   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2015-003999-79-Outside-EU/EEA   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-FR   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-EE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
Reumaflex
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy
RIL-1RA
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands
Rilonacept
   Montefiore Medical Center
      2008   Phase 2   NCT00534495   United States
   Regeneron Pharmaceuticals
      2005   Phase 1   NCT01803321   United States
Risedronate sodium
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
RO 487-7533/F01
   F. Hoffmann-La Roche Ltd
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2009-011593-15-IT   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
RO 487-7533/F10
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom
RO 487-7533/F10-04
   F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 1   EUCTR2013-005212-98-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 1   EUCTR2013-005212-98-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      -   Phase 1   EUCTR2013-005212-98-FR   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
RO-actemra
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany
RO4877533
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 4   EUCTR2012-000444-10-IT   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-SE   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-NL   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-ES   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2007-000872-18-NO   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-PL   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-HU   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-GB   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-DE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-BE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-ES   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 1   EUCTR2015-000435-33-FR   Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   ROCHE
      2008   -   EUCTR2007-000872-18-IT   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-ES   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany
Roactemra
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 4   EUCTR2012-000444-10-IT   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-PL   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-HU   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-GB   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-DE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-BE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2014   Phase 1   EUCTR2013-005212-98-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 1   EUCTR2013-005212-98-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2009-011593-15-IT   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 1   EUCTR2015-000435-33-FR   Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   Hoffmann-La Roche
      2013   Phase 3   NCT01727986   Brazil
      2012   Phase 3   NCT01673919   France
      2012   Phase 3   NCT01667471   Germany
      2012   Phase 3   NCT01575769   Poland;Russian Federation
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
   Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-ES   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
   Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom
Roactemra 20 MG/ML, concentrado para solucióN para perfusióN
   F. Hoffmann-La Roche Ltd
      2009   Phase 3   EUCTR2009-011593-15-ES   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
RVG 104433
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
RVG 28636
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States
SAR153191
   Sanofi
      2018   Phase 2   NCT02991469   Argentina;Bulgaria;Canada;Chile;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   sanofi-aventis recherche & développement
      2021   Phase 2   EUCTR2015-004000-35-IE   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2021   Phase 2   EUCTR2015-004000-35-BG   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2015-004000-35-PL   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-NL   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-DE   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-003999-79-DE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-IT   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-FI   Argentina;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-ES   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-EE   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-PL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-NL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-IT   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-FI   Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-ES   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-CZ   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-004000-35-CZ   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2015-003999-79-Outside-EU/EEA   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-FR   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-EE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
SAR153191 (REGN88)
   sanofi-aventis recherche & développement
      2017   Phase 2   EUCTR2015-004000-35-FR   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
Sarilumab
   Sanofi
      2018   Phase 2   NCT02991469   Argentina;Bulgaria;Canada;Chile;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   NCT02776735   Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   sanofi-aventis recherche & développement
      2021   Phase 2   EUCTR2015-004000-35-IE   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2021   Phase 2   EUCTR2015-004000-35-BG   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2015-004000-35-PL   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-NL   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-004000-35-DE   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2015-003999-79-DE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-IT   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-FI   Argentina;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-ES   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004000-35-EE   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Ireland;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-PL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-NL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-IT   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-FI   Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-ES   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003999-79-CZ   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-004000-35-CZ   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2015-003999-79-Outside-EU/EEA   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-FR   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2015-003999-79-EE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
SB4
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
SB5
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
Secukinumab
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2018-002521-30-IT   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2017   Phase 3   EUCTR2016-003761-26-ES   Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 3   EUCTR2018-002521-30-ES   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2018-002521-30-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
      2019   Phase 3   EUCTR2018-002521-30-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2017   Phase 3   EUCTR2016-003761-26-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-GB   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003761-26-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2018-002521-30-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Türkiye;United States
   Novartis Pharmaceuticals
      2025   -   NCT06431750   -
Sedatives/hypnotics,other
   University of Oulu
      2017   Phase 4   NCT03069638   Finland
Solumedrol
   Sohag University
      2024   Phase 3   NCT06463379   Egypt
Somatropin
   Pfizer Inc
      -   -   EUCTR2014-004105-32-Outside-EU/EEA   France
   Pharmacia & Upjohn S.A.
      -   -   EUCTR2014-004104-30-Outside-EU/EEA   France
   Royal Hospital For Sick Children, Yorkhill Division
      2004   -   EUCTR2004-004153-25-GB   United Kingdom
SSGJ-613
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2021   Phase 1   NCT05027373   China
Standard regimen
   Nourhan Elsherif
      2023   Phase 2/Phase 3   NCT05871086   Egypt
Steroid
   Sohag University
      2021   Phase 3   NCT04775225   Egypt
SUB180983
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom
Sulfasalazine
   Leiden University Medical Centre
      2016   Phase 4   EUCTR2014-003260-20-NL   Netherlands
   Pfizer
      2010   Phase 4   NCT00637780   Canada;Mexico;United States
TC-MSC
   University Medical Center Utrecht
      2014   -   EUCTR2012-002067-10-NL   Netherlands
Thiotepa
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
TNF inhibitor
   Oslo University Hospital
      2024   Phase 4   NCT06653634   Norway
Tnfi (tumor necrosis factor inhibitor) medication
   Duke University
      2025   Phase 3   NCT06654882   -
Tnfr:FC
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
Tocilizumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France
   AbbVie
      2023   Phase 3   NCT05609630   Australia;Austria;Brazil;China;Germany;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France
   Children's Hospital of Chongqing Medical University
      2017   -   ChiCTR-OPB-17013704   China
      2016   -   ChiCTR-OPC-17011391   China
   Children's Hospital, Zhejiang University School of Medicine
      2023   Phase 0   ChiCTR2300070171   China
   Chugai Pharmaceutical
      2005   Phase 3   NCT00144625   -
      2004   Phase 3   NCT00144664   -
      2004   Phase 3   NCT00144612   -
      2004   Phase 3   NCT00144599   -
   Chugai Pharmaceutical Co., Ltd.
      2005   Phase 3   JPRN-jRCT2080220017   -
   Division of Rheumatology & Clinical Immunology, Jichi Medical University
      2008   -   JPRN-UMIN000001457   Japan
      2008   -   JPRN-UMIN000001250   Japan
   Duke University
      2025   Phase 3   NCT06654882   -
   Eli Lilly Japan K.K.
      2019   Phase 3   JPRN-jRCT2080224972   Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;India;Israel;Italy;Japan;Mexico;Poland;Spain;Turkey;United Kingdom
   Eli Lilly and Company
      2020   Phase 3   NCT04088396   Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom
   Eric B. Suhler
      2013   Phase 1/Phase 2   NCT01603355   United States
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 4   EUCTR2012-000444-10-IT   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-PL   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-HU   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-GB   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-DE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2015   Phase 1   EUCTR2015-000435-33-BE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2009-011593-15-ES   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 1   EUCTR2015-000435-33-FR   Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom
   Hayato Yamazaki
      2023   Phase 3   JPRN-jRCT2031230402   Australia;Japan;United States
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China
      2014   Phase 1   NCT02165345   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   NCT01904292   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   NCT01904279   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 4   NCT01734382   Argentina;Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;United States
      2013   Phase 3   NCT01727986   Brazil
      2012   Phase 3   NCT01673919   France
      2012   Phase 3   NCT01667471   Germany
      2012   Phase 3   NCT01575769   Poland;Russian Federation
      2012   Phase 1   NCT01455701   Argentina;Belgium;Canada;France;Germany;Hungary;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   NCT00988221   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
   ROCHE
      2008   -   EUCTR2007-000872-18-IT   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-ES   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany
   Shenzhen Children's Hospital
      2017   -   ChiCTR-INR-17011829   China
   Tufts Medical Center
      2009   -   NCT00868751   United States
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom
   University of Oklahoma
      2009   -   NCT00862758   United States
   Yokohama City University Hospital Department of Pediatrics
      2016   -   JPRN-UMIN000024178   Japan
Tocilizumab roche
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SE   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-NL   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-000872-18-ES   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2007-000872-18-NO   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
   F. Hoffmann-La Roche Ltd.
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom
Tocilizumab SC
   F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 1   EUCTR2013-005212-98-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 1   EUCTR2013-005212-98-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
      -   Phase 1   EUCTR2013-005212-98-FR   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States
Tofacitinib
   Duke University
      2025   Phase 3   NCT06654882   -
   PFIZER INC.
      2013   Phase 2   EUCTR2011-004915-22-IT   Argentina;Belgium;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;United Kingdom
      2012   -   EUCTR2011-004914-40-IT   Argentina;Hungary;Italy;Mexico;Poland;Russian Federation
   Pfizer
      2016   Phase 3   NCT02592434   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2013   Phase 2/Phase 3   NCT01500551   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2011-004914-40-SK   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia
      2012   -   EUCTR2011-004914-40-PL   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia
      2012   Phase 1   EUCTR2011-004914-40-HU   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2022   Phase 2;Phase 3   EUCTR2011-004915-22-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-HU   Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom
   Pfizer Inc.
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
Tofacitinib citrate
   PFIZER INC
      2020   Phase 3   EUCTR2017-002018-29-IT   Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2019   Phase 3   EUCTR2015-001438-46-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 66 Hudson Boulevard East, New York, New York 10001
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
Tofacitinibe citrate
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 66 Hudson Boulevard East, New York, New York 10001
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
Triamcinolone hexacetonide
   Oslo University Hospital
      2020   Phase 4   EUCTR2019-000889-38-NO   Norway
Triamcinolone hexacetonide 20 MG/ML
   Oslo University Hospital
      2020   Phase 4   NCT04614311   Norway
Upadacitinib
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 1   EUCTR2018-000715-25-IT   Germany;Hungary;Italy;Spain;Sweden;United States
   AbbVie
      2023   Phase 3   NCT05609630   Australia;Austria;Brazil;China;Germany;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 1   NCT03725007   Canada;Germany;Hungary;Israel;Italy;Japan;Puerto Rico;Spain;Sweden;United States
   AbbVie Deutschland GmbH & Co. KG
      2023   Phase 1   EUCTR2018-000715-25-SE   Canada;Germany;Hungary;Italy;Spain;Sweden;United States
      2019   Phase 1   EUCTR2018-000715-25-HU   Germany;Hungary;Italy;Spain;United States
      2019   Phase 1;Phase 3   EUCTR2018-000715-25-ES   Germany;Hungary;Italy;Spain;United States
      2019   Phase 1   EUCTR2018-000715-25-DE   Germany;Hungary;Italy;Spain;Sweden;United States
   Hayato Yamazaki
      2023   Phase 3   JPRN-jRCT2031230402   Australia;Japan;United States
   Yamazaki Hayato
      2023   Phase 1   JPRN-jRCT2031220577   Germany;Hungary;Israel;Italy;Japan;Puerto Rico;Spain;United States
Vimovo 250/20
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01544114   United States
Vimovo 375/20
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01544114   United States
Vimovo 500/20
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01544114   United States
Vitamin B3
   UMC Utrecht
      2019   Phase 1;Phase 2   EUCTR2018-002245-11-NL   Netherlands
VSL#3
   Assistance Publique - Hôpitaux de Paris
      2017   -   NCT03092427   France
Xeljanz
   Pfizer
      2024   -   NCT05754710   Korea, Republic of
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2022   Phase 2;Phase 3   EUCTR2011-004915-22-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2015-001438-46-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-001438-46-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2018   Phase 3   EUCTR2015-001438-46-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil